Andrew Obenshain

2022

In 2022, Andrew Obenshain earned a total compensation of $1.8M as Chief Executive Officer at bluebird bio, a 80% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$386,280
Option Awards$421,830
Salary$643,390
Stock Awards$351,000
Other$12,200
Total$1,814,700

Obenshain received $643.4K in salary, accounting for 35% of the total pay in 2022.

Obenshain also received $386.3K in non-equity incentive plan, $421.8K in option awards, $351K in stock awards and $12.2K in other compensation.

Rankings

In 2022, Andrew Obenshain's compensation ranked 1,887th out of 5,505 executives tracked by ExecPay. In other words, Obenshain earned more than 65.7% of executives.

ClassificationRankingPercentile
All
1,887
out of 5,505
66th
Division
Manufacturing
999
out of 2,984
67th
Major group
Chemicals And Allied Products
420
out of 1,339
69th
Industry group
Drugs
385
out of 1,242
69th
Industry
Biological Products, Except Diagnostic Substances
99
out of 287
66th
Source: SEC filing on April 28, 2023.

Obenshain's colleagues

We found three more compensation records of executives who worked with Andrew Obenshain at bluebird bio in 2022.

2022

Jason Cole

bluebird bio

Chief Strategy & Financial Officer former

2022

Richard Colvin

bluebird bio

Chief Medical Officer

2022

Thomas Klima

bluebird bio

Chief Commercial and Operating Officer

News

You may also like